We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00586287
First Posted: January 4, 2008
Last Update Posted: April 2, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Samuel Henz, Cantonal Hospital of St. Gallen
  Purpose

Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values.

The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.


Condition Intervention Phase
Pulmonary Embolism Atrial Fibrillation Hip Replacement Postoperative Knee Replacement Postoperative Other: Algorithm for phenprocoumon Other: algorithm for phenprocoumon Drug: Phenprocoumon Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon

Resource links provided by NLM:


Further study details as provided by Samuel Henz, Cantonal Hospital of St. Gallen:

Primary Outcome Measures:
  • rate of patients with therapeutic INR levels on day six without anticoagulation-related complications during the loading period [ Time Frame: after 30 days ]

Secondary Outcome Measures:
  • the time-course of the INR-values, the rate of excessive INR-values, defined as INR >3.5 within 10 days, the rate of minor and major bleeding complications, the length of stay, and death within 30 days [ Time Frame: 30 days ]

Enrollment: 302
Study Start Date: January 2007
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
Other: Algorithm for phenprocoumon
Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
Other Name: Marcoumar
Experimental: B
Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
Other: algorithm for phenprocoumon
Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
Other Name: Marcoumar
Active Comparator: C
The physician chooses the loading dose of phenprocoumon according to his/her experience
Drug: Phenprocoumon
Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
Other Name: Marcoumar

Detailed Description:

Background:

The presently available oral anticoagulants have a very narrow therapeutic range but the interindividual demands to achieve therapeutic anticoagulation (=loading dose) varies greatly. Overanticoagulation is a major cause of bleeding complications, whereas insufficient anticoagulation is associated with thromboembolic disease and possibly prolonged hospital stay. A model to predict the loading dose with phenprocoumon (Marcoumar®) is therefore highly desirable.

In a retrospective analysis of 300 inpatients (152 medical, 148 orthopedic patients) of the Cantonal Hospital of St. Gallen our group identified clinical predictors for the loading dose of phenprocoumon and two dosing algorithms were developed (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.).

In order to validate the safety and efficacy of these dosing algorithms we plan this prospective interventional study with three equally sized arms: dosing according to algorithm 1, dosing according to algorithm 2 or dosing according to the estimate of the physician (control).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consecutive inpatients of the internal medicine and the orthopedic surgery department of the Cantonal Hospital of St. Gallen needing new onset oral anticoagulation

Exclusion Criteria:

  • Patients with prior oral anticoagulation with coumarines within less than 6 weeks,
  • patents, who received vitamin-K supplements within less than one week before the onset of oral anticoagulation,
  • patients with liver cirrhosis other than Child A,
  • pregnant women (pregnancy has to be excluded in women of childbearing age),
  • patients younger than 18 years, and
  • patients unwilling or unable to give informed consent
  • patients with (clinically diagnosed) dementia and
  • persons with insufficient German, French, Italian or English language skills)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00586287


Locations
Switzerland
Cantonal Hospital St. Gallen
St. Gallen, Switzerland, CH-9007
Sponsors and Collaborators
Cantonal Hospital of St. Gallen
Investigators
Principal Investigator: Samuel Henz, MD MPH Cantonal Hospital St. Gallen, Switzerland
Study Director: Wolfgang Korte, MD IKCH - Laboratory St. Gallen Switzerland
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Samuel Henz, Samuel Henz MD MPH, Cantonal Hospital of St. Gallen
ClinicalTrials.gov Identifier: NCT00586287     History of Changes
Other Study ID Numbers: EKSG 06/022/1B
Swissmedic 2006 DR 4 2 7 9
First Submitted: December 20, 2007
First Posted: January 4, 2008
Last Update Posted: April 2, 2012
Last Verified: March 2012

Keywords provided by Samuel Henz, Cantonal Hospital of St. Gallen:
Phenprocoumon
Dosing algorithm
loading dose

Additional relevant MeSH terms:
Atrial Fibrillation
Embolism
Pulmonary Embolism
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Lung Diseases
Respiratory Tract Diseases
Phenprocoumon
Anticoagulants